Cargando…
Modified-Release Hydrocortisone in Congenital Adrenal Hyperplasia
CONTEXT: Standard glucocorticoid therapy in congenital adrenal hyperplasia (CAH) regularly fails to control androgen excess, causing glucocorticoid overexposure and poor health outcomes. OBJECTIVE: We investigated whether modified-release hydrocortisone (MR-HC), which mimics physiologic cortisol sec...
Autores principales: | Merke, Deborah P, Mallappa, Ashwini, Arlt, Wiebke, Brac de la Perriere, Aude, Lindén Hirschberg, Angelica, Juul, Anders, Newell-Price, John, Perry, Colin G, Prete, Alessandro, Rees, D Aled, Reisch, Nicole, Stikkelbroeck, Nike, Touraine, Philippe, Maltby, Kerry, Treasure, F Peter, Porter, John, Ross, Richard J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063257/ https://www.ncbi.nlm.nih.gov/pubmed/33527139 http://dx.doi.org/10.1210/clinem/dgab051 |
Ejemplares similares
-
OR25-02 A Phase 3 Study of a Modified-Release Hydrocortisone in the Treatment of Congenital Adrenal Hyperplasia
por: Merke, Deborah P, et al.
Publicado: (2020) -
RF09 | PSAT70 Comparison of Prednisolone Versus Modified-release Hydrocortisone (Efmody) in the Treatment of Congenital Adrenal Hyperplasia (CAH)
por: Merke, Deborah P, et al.
Publicado: (2022) -
SAT304 Improved Biochemical Control With Dose Reduction In Chronic Glucocorticoid Therapy: A Phase III Extension Study Of Chronocort (Efmody) In The Treatment Of Congenital Adrenal Hyperplasia (CAH)
por: Ross, Richard John M, et al.
Publicado: (2023) -
Alterations in Hydrocortisone Pharmacokinetics in a Patient With Congenital Adrenal Hyperplasia Following Bariatric Surgery
por: Mallappa, Ashwini, et al.
Publicado: (2017) -
Management challenges and therapeutic advances in congenital adrenal hyperplasia
por: Mallappa, Ashwini, et al.
Publicado: (2022)